Clinical trials: Hematopoietic
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Role of Gut Microbiome in Cancer Therapy
This study examines how gut microbiome can affect cancer therapy in cancer patients undergoing cancer therapy or stem cell transplant. The human microbiome affects the way some cancer drugs are metabolized in the human body.
- Trial name
- NCT05112614
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- 3 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Mayo Clinic
Graft Failure, Sickle Cell Disease
Allo HSCT for High Risk Hemoglobinopathies
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation…
- Conditions
- Graft Failure, Sickle Cell Disease, Hemoglobinopathies
- Trial name
- NCT06872333
- Testing
- Alemtuzumab, Total Body Irradiation, Cell Infusion
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Juvenile Myelomonocytic Leukemia
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Giving chemotherapy drugs, such as R115777, isotretinoin, cytarabine, and fludarabine, before a donor bone marrow transplant or an umbilical cord transplant helps stop the growth of cancer cells.
- Trial name
- NCT00025038
- Testing
- tipifarnib, isotretinoin, fludarabine phosphate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after transplantation with TCR alpha/beta grafts depletion in patient with…
- Conditions
- Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation, Graft Failure
- Trial name
- NCT03019809
- Testing
- G-CSF for Conditioning before HSCT., Plerixafor for Conditioning before HSCT.
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hodgkin Lymphoma
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical…
- Trial name
- NCT06812858
- Testing
- Nivolumab, Pembrolizumab
- Where
- 4 sites in Kazakhstan, Russia
- Volunteers
- 83 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Delirium
Prevention of Delirium After Bone Marrow Transplantation
The purpose of this study is to find out if using bright light sessions during bone marrow transplant can prevent people from developing confusion also known as delirium.
- Trial name
- NCT01700816
- Testing
- Bright light therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma
The 3-drug therapy of Bortezomib-Melphalan-Prednisolone (VMP) is a standard therapy that is commonly used currently in South Korea as a first-line treatment for treatment-naïve patients with multiple myeloma who are ineligible…
- Trial name
- VISION (NCT04151615)
- Where
- 24 sites in South Korea
- Volunteers
- 203 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
This phase I/II trial studies the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, donor…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT00789776
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
Metachromatic Leukodystrophy (MLD)
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
This is a Phase I/II clinical trial of gene therapy for treating Metachromatic leukodystrophy (MLD) using a safety and efficacy improved self-inactivating lentiviral vector TYF-ARSA to transduce patient-derived hematopoietic stem…
- Trial name
- NCT07046338
- Testing
- Lentiviral TYF-ARSA correction of patient's autologous HSCs
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Allogeneic Hematopoietic Stem Cell
Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see if fecal microbiota transplantation (FMT) will prevent the future development of CDI. This is also known as fecal bacteriotherapy or stool transplant.
- Trial name
- NCT02269150
- Testing
- fecal microbiota transplantation (FMT), No fecal microbiota transplantation (FMT), routine management
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft-versus-host-disease, Graft Vs Host Disease
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
In this trial, the investigators will begin to explore the possibility that, as in mice, JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) while retaining engraftment…
- Trial name
- NCT04131738
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Wiskott-Aldrich Syndrome
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding.
- Trial name
- NCT02064933
- Where
- 43 sites in United States, Canada
- Volunteers
- 305 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adult B Acute Lymphoblastic Leukemia
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed Refractory (R/R) adult acute lymphoblastic…
- Trial name
- NCT04626726
- Testing
- CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Preterm Birth, Umbilical Cord Clamping
Umbilical Cord Clamping Methods and Stem Cell Counts in Preterm Infants
This study evaluates the effect of different umbilical cord clamping methods on peripheral blood hematopoietic stem cell counts in preterm newborns.
- Trial name
- NCT07385326
- Testing
- Immediate Cord Clamping, Delayed Cord Clamping, Umbilical Cord Milking
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Era Tufan Benli
Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and…
- Trial name
- NCT03425526
- Testing
- Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Sickle Cell Disease and Thalassemia
Allograft for Sickle Cell Disease and Thalassemia
The design of the study incorporates the following features: 1. This is a phase II study to determine the safety and therapeutic potential of a new transplant approach (disease-free survival, graft versus myeloma effect) and to…
- Trial name
- NCT02038478
- Testing
- Donor Stem Cell Transplantation
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
This phase I trial studies pretargeted radioimmunotherapy and donor peripheral blood stem cell transplant employing fludarabine phosphate and total-body irradiation (TBI) to treat patients with high-risk acute myeloid leukemia…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00988715
- Testing
- Pretargeted Radioimmunotherapy, Cyclosporine, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft-vs-Host Disease
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
This trial will test the hypothesis that the combination of sirolimus, mycophenolate mofetil, and bortezomib will be effective in preventing both acute and chronic GVHD after reduced intensity allogeneic stem cell transplantation.
- Trial name
- NCT00548717
- Testing
- Sirolimus, Mycophenolate mofetil, Bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Unrecognized Condition: Mature B or T-cell Neoplasm
Cyclosporine Plus Methotrexate or Alemtuzumab
The primary aim of the study was to compare the efficacy of the procedure in terms of event-free survival between patients receiving cyclosporine (CsA) plus either alemtuzumab (CAMPATH-1H ) or methotrexate (MTX) after matched…
- Trial name
- NCT02701517
- Testing
- Cyclosporine + METHOTREXATE, Cyclosporine + CAMPATH-1H
- Where
- 5 sites in Poland, Spain
- Volunteers
- 72 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.